Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

68 gallium labelled FF58 - Advanced Accelerator Applications

Next Previous
X
Search
Drug Profile

68 gallium labelled FF58 - Advanced Accelerator Applications

Alternative Names: 68Ga-FF-58

Latest Information Update: 23 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advanced Accelerator Applications
  • Developer Advanced Accelerator Applications; Novartis
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Brain cancer; Glioblastoma

Most Recent Events

  • 16 Oct 2023 Phase-I clinical trials in Solid tumours (Diagnosis, Late-stage disease, Inoperable/Unresectable, Recurrent, Metastatic disease) in Switzerland (Parenteral) (NCT05977322)
  • 19 Jan 2021 Advanced Accelerator Applications plans a phase I trial for Solid tumours (Diagnosis) in March 2021 (IV, Injection) (NCT04712721)
  • 19 Jan 2021 Preclinical trials in Brain cancer (Diagnosis) in France (IV) before January 2021 (NCT04712721)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top